precisionmedicineonline34m
Intellia Therapeutics Doses First Patient in Phase III Hereditary Angioedema Trial of CRISPR Drug
The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.
precisionmedicineonline1h
Base Editing Being Tested to Treat Rare Genetic Immune Disorder in NIAID-Sponsored Trial
In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...
precisionmedicineonline20h
NICE Recommends NHS England Provide AstraZeneca's Tagrisso for Adjuvant EGFR-Mutated NSCLC
The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.
precisionmedicineonline22h
Neogap Therapeutics Begins Evaluating Personalized T-Cell Therapy in Advanced Colorectal Cancer
The Swedish firm has treated the first two patients in a Phase I/II trial of the autologous neoantigen-directed lymphocyte therapy.
precisionmedicineonline23h
Cartesian Therapeutics Kicking off Phase III Cell Therapy Trial in Myasthenia Gravis
The company also continues to study Descartes-08 in other autoimmune diseases and has plans for a basket trial in pediatric patients.